This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jackson, J. G. Articles by Yee, D. Search for Related Content PubMed PubMed Citation Articles by Jackson, J. G. Articles by Yee, D.

Elevated Levels of p66 Shc Are Found in Breast Cancer Cell Lines and Primary Tumors with High Metastatic Potential¹

Divisions of Medical Oncology [J. G. J., G. M. C., D. Y.] and Endocrinology [T. Y.], Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78284-7884

	ABSTRACT

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
The adapter molecule Shc has been implicated in specific steps of metastasis. In the current study, we show that the expression and activation of the p66 Shc isoform increased in a highly metastatic variant (F-11) of the human breast cancer cell line MDA-MB-231 compared to the parent cell line, whereas the p46 and p52 Shc isoforms were unchanged. Despite reports that p66 Shc can negatively regulate epidermal growth factor signaling to the mitogen-activated protein kinase pathway, we found no change in epidermal growth factor-stimulated activation of mitogen-activated protein kinase in the F-11 cell line. We determined the level of Shc expression by immunoblot in primary breast cancer specimens obtained from patients with or without axillary node involvement. p66 Shc expression increased in tumors obtained from node-positive patients (Spearman correlation coefficient = 0.43377; P = 0.0058) compared to the node-negative specimens. Furthermore, increasing levels of p66 Shc correlated with an increasing number of positive nodes (P = 0.032). This study shows that p66 Shc expression increased in cultured breast cancer cells selected for metastasis and in primary human breast cancer specimens obtained from patients with lymph node involvement, suggesting a possible role for Shc in human breast cancer metastasis.

	INTRODUCTION

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Breast cancer is a lethal disease because of uncontrolled proliferation at metastatic sites. Metastasis is a complex, multistep process involving recruitment of blood vessels, motility and invasion of transformed cells into surrounding stroma, and intravasation of tumor cells into the vasculature. After reaching the circulation or lymphatic channels, some metastatic cells must then arrest in the intraluminal space, adhere to the endothelial walls, extravasate into the organ, and interact with the new environment (1) . Each of these steps is, at least in part, controlled by various growth factors, adhesion molecules, and their receptor tyrosine kinases. Growth factors that are known to be involved in cell motility, invasion, or migration of various cell types include nerve growth factor (2 , 3) , fibroblast growth factor (2 , 4 , 5) , platelet-derived growth factor (2 , 6) , EGF³ (2 , 7) , keratin growth factor (3) , hepatocyte growth factor (3 , 8) , interleukin 2 (9) , and insulin and IGFs (10) .

Many growth factors, cytokines, and adhesion molecules exert their effects by activating specific tyrosine kinases. The activated receptor allows the docking of additional SH2 and PTB domain containing adapter molecules that coordinate and integrate intracellular signaling events. Interestingly, the adapter molecule Shc is activated by each of the receptors for the ligands listed, suggesting a possible role for Shc in the metastatic process. Shc is a SH2 and PTB domain-containing protein encoded by one gene that produces three isoforms with molecular weights of 46,000, 52,000, and 66,000 respectively (11) . Each isoform can serve as a substrate for activated cytoplasmic or receptor tyrosine kinases via either PTB or SH2 domains and can then associate with other SH2 domains containing signaling molecules, such as Grb2. It has previously been shown that Shc can amplify the motogenic signal delivered by the hepatocyte growth factor receptor Met in BN-14 mouse bile duct and A549 lung carcinoma cells (8) . Furthermore, Shc binding has been shown to be essential in cell motility induced by the nerve growth factor receptor trkA (3) . Even more compelling evidence for a role by Shc in metastasis was found in a study of transgenic mice strains expressing polyomavirus middle T antigen with a mutated Shc binding site (12) . Focal mammary tumors arose in the female transgenic mice, but surprisingly, there was reversion of the mutated middle T Shc binding site to wild-type in a number of the metastatic tumors forming in these mice. This important study demonstrates a strong, positive selective pressure for normal Shc function in the establishment of breast cancer metastases.

In the current study, we used a highly metastatic variant (F-11) isolated from a xenograft bone metastasis of breast cancer cell line MDA-MB-231 to investigate Shc signaling. Using EGF to activate Shc in these cells, we found that phosphorylation of the p66 isoform was greatly increased in the metastatic variant compared to the parental cell line. We also found that levels of p66 Shc protein were increased in F-11. No significant difference in EGF-induced activation of MAP kinase was detected in F-11 compared to the parental MDA-MB-231 cell line. To further investigate the importance of Shc in breast cancer metastasis, we measured levels of Shc protein in primary breast cancer specimens. In breast cancer specimens associated with lymph node metastases, we found that p66 Shc expression was elevated and that increased expression of p66 Shc correlated with a greater number of positive nodes. In light of previous work, these data further implicate Shc in the metastatic process and suggest that the p66 Shc isoform may be involved.

	MATERIALS AND METHODS

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Reagents.
All chemicals and reagents were purchased from Sigma (St. Louis, MO) unless otherwise noted. MAP kinase and Shc antibodies were purchased from Upstate Biotechnology (Lake Placid, NY). Phospho-specific (activated) MAP kinase was purchased from New England Biolabs (Beverly, MA); RC-20 antiphosphotyrosine was purchased from Transduction Laboratories (Lexington, KY); horseradish peroxidase-linked antirabbit antibody and rainbow molecular weight markers were purchased from Amersham Pharmacia Biotech. IGF-I was purchased from Gro Pep (Adelaide, Australia). Acrylamide/bis was purchased from Bio-Rad (Hercules, CA). 435A cells were a gift of Nils Brunner (Finneslab, Copenhagen, Denmark) and have been described previously (13) ; MDA-MB-231 cells were originally purchased from American Type Culture Collection (Manassas, VA). The F-11 metastatic variant was created in the laboratory of Dr. Toshiyuki Yoneda (University of Texas Health Science Center at San Antonio, San Antonio, TX) and will be described elsewhere.⁴ Briefly, an athymic mouse received an intracardiac injection of MDA-MB-231 cells, and bone metastases that formed were established in vitro after 11 serial passages in vivo.

Cell Stimulation and Lysis.
For stimulation experiments, cells were treated as described previously (14) . After cells were allowed to attach overnight in serum-containing medium, cells were washed and incubated with SFM for 24 h. To stimulate cells, medium was replaced with SFM plus indicated growth factors for 10 min at the following concentrations: 5 nM (40 ng/ml) IGF-I and 50 ng/ml EGF. Cells were washed twice in ice-cold PBS and lysed with 500 µl/10-cm plate of TNESV buffer. Protein concentration of the cleared lysates was determined by the copper-bicinchoninic acid method with a Pierce Laboratory kit (Rockford, IL).

Immunoprecipitations.
All steps were performed on a platform rocker at 4°C. Equal amounts of protein were precleared with 25 µl of protein A-agarose for 30 min and then incubated overnight with 2 µl of Shc antibody. Next, 25 µl of protein A-agarose (Pierce) was added for 4 h, followed by three washes with TNESV buffer. Beads were resuspended in 2x Laemmli loading buffer with 30 mg/ml DTT, boiled, and then separated by 9% SDS-PAGE.

Preparation of Breast Tumor Specimens.
Twenty primary tumor specimens from patients with pathological evidence of disease in the lymph nodes and 19 node-negative breast tumor specimens obtained from the San Antonio Tumor Bank were separated into two blinded groups. These tumors were obtained previously for the measurement of ER. Frozen, pulverized tumor powder (50 mg) was lysed in 500 µl of TNESV buffer. After centrifugation, protein concentration of the supernatant was determined as described above. Tumor protein (150 µg; 13 specimens were run on one gel, seven from one blinded group and six from the other), 50 µg of 435A control protein, and rainbow marker (15 total lanes) were separated by SDS-PAGE on three gels.

Immunoblotting.
After SDS-PAGE, proteins were transferred overnight to nitrocellulose membranes (Bio-Rad). All blotting steps were carried out at room temperature with gentle rocking as described previously (14) . The membranes were blocked in 5% nonfat dry milk in TBST [0.15 M NaCl, 0.01 M Tris-HCl (pH 7.4), and 0.05% Tween 20]. For antiphosphotyrosine blotting with RC-20, membranes were washed five times for more than 30 min with TBST after blocking, incubated with a 1000:1 dilution in TBST for 2 h, and washed. Chemiluminescence was then performed as described below. Shc blots were incubated with a 2000:1 dilution of the indicated antibody in blocking buffer for 1 h. After washing, blots were incubated with a 2000:1 dilution of horseradish peroxidase-linked antirabbit secondary antibody in blocking buffer for 1 h, followed by further washing. Enhanced chemiluminescence was performed according to the manufacturer’s instructions (Pierce).

Densitometry and Statistics.
Densitometry was performed by scanning the radiographs (ScanJet IIcx; Hewlett-Packard) and then analyzing the bands with ImageTool version 2.0 software (University of Texas Health Science Center at San Antonio). Radiographs with shorter exposure times than those shown in Fig. 3 were used for quantitating the p52 and p46 Shc bands. Background-subtracted densitometry units were normalized among the different gels by dividing by the values for the 435A control cell line.

View larger version (45K): [in this window] [in a new window] [Download PPT slide]   Fig. 3. Shc expression in node-positive versus node-negative primary breast tumors. Total protein (150 µg) from lysates of blinded breast tumor specimens (seven node-positive specimens and six node-negative specimens) and 50 µg of protein from control 435A cells were separated by SDS-PAGE and immunoblotted for Shc blots. A representative immunoblot is shown (1 of 3 blots). A total of 39 specimens was studied for Shc expression. Molecular weight markers are indicated at the right. Data shown are representative of two separate experiments.

	RESULTS

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Shc Activation and Expression in MDA-MB-231 and F-11.
We first compared Shc activation in MDA-MB-231 and a metastatic variant of this cell line selected from a bone metastasis, F-11. After EGF treatment and Shc immunoprecipitation, antiphosphotyrosine immunoblotting shows MDA-MB-231 cells strongly phosphorylated the p46 and p52 isoforms of Shc, but only a weak activation of p66 Shc was observed (Fig. 1 , top). In contrast, F-11 cells showed a much stronger activation of p66 Shc in response to EGF. Activation of the p46 and p52 isoforms was not significantly different in F-11 compared to parental MDA-MB-231 cells (Fig. 1 , top). IGF-I treatment did not result in activation of any Shc isoform in either cell line (Fig. 1 , top). After immunoblotting MDA-MB-231 and F-11 cell lysates for Shc, we found that the levels of p46 and p52 isoforms were unchanged between the two cell lines, but that F-11 cells had a 3-fold increased expression of the p66 isoform (Fig. 1 , bottom).

View larger version (25K): [in this window] [in a new window] [Download PPT slide]   Fig. 1. Activation and expression of p66 Shc in the MDA-MB-231 cell line versus the F-11 metastatic variant. Top, serum-starved 70% confluent cell monolayers were treated for 10 min with SFM, EGF, or IGF-I as indicated above the lanes. Cell lysates were immunoprecipitated with Shc antibody, separated by SDS-PAGE, and antiphosphotyrosine immunoblotted. Bottom, SFM-treated cell lysates were separated by SDS-PAGE and Shc immunoblotted. Migration of various Shc isoforms is indicated at the left; molecular weight markers are indicated at the right. Data shown are representative of at least three independent experiments. Levels of p66 Shc were significantly higher in F-11 cells compared to MDA-MB-231 cells (P = 0.0019), whereas levels of p52 (P = 0.84) and p46 (P = 0.22) did not differ between the cell lines.

View larger version (61K): [in this window] [in a new window] [Download PPT slide]   Fig. 2. Expression and activation of MAP kinase in the MDA-MB-231 cell line versus the F-11 metastatic variant. Serum-starved 70% confluent cell monolayers were treated for 10 min with SFM, EGF, or IGF-I as indicated above the lanes. Cell lysates were separated by SDS-PAGE and immunoblotted for phospho-MAP kinase (top) or total MAP kinase (bottom). Molecular weight markers are indicated at the right. Data shown are representative of two separate experiments.

	DISCUSSION

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

The observation that the p66 Shc isoform was increased in the F-11 cells and in the node-positive breast tumor specimens was unexpected. No transforming or growth-promoting properties of this isoform have been reported: (a) it does not transform mouse fibroblasts in vitro (11) ; (b) it decreases (15) or does not influence activation of MAP kinases; and (c) it inhibits fos promoter activation. However, these studies represent data from only three cell lines, Cos-1, HeLa, and Chinese hamster ovary cells, that overexpress p66 Shc by transfection. Furthermore, experiments on phenotypic changes in p66 Shc-expressing cells were limited to transformation. Few other data exist for a functional role for p66 Shc, particularly endogenous p66 Shc.

If p66 Shc participates in the metastatic pathway, then clearly additional downstream molecules must be involved. In human tissues, it has been suggested that activation of MAP kinase results in more aggressive clinical behavior (16) . The majority of data show that p52 Shc mediates signaling by activating the MAP kinase pathway via its association with the Grb2/sos complex, which activates ras. In the F-11 cell line, we found no difference in MAP kinase activation after EGF treatment compared to the MDA-MB-231 parental cells, but we consistently found that F-11 cells had a slightly higher level of basal activation. It is not known whether this slight increase was due to p66 Shc up-regulation or whether it was even physiologically significant. The high levels of basal MAP kinase activation in both MDA-MB-231 and F-11 cell lines make MAP kinase stimulation experiments more difficult to interpret, although our data suggest that increased signaling through MAP kinase alone does not account for the enhanced metastatic behavior of the variant cell lines. Our data show that the elevated levels of p66 Shc expression did not influence MAP kinase signaling in the F-11 cell line. In addition, the cell lines and tumor tissues we examined were obtained from fully transformed malignant breast epithelial cells, suggesting that p66 Shc does not play a role in the transformation of these cells. However, higher levels of p66 Shc were observed in specimens with higher metastatic potential, and it is possible that p66 Shc functions in motility and invasion pathways distinct from MAP kinase.

It is also possible that Shc may deliver its signal in the metastatic process by a Grb2-independent pathway. It has been shown that Shc can exert mitogenic (17) and antiapoptotic (18) effects independent of ras signaling. Shc also binds other unidentified tyrosine-phosphorylated proteins other than Grb2 (19) . Even phosphatidylinositol 3'-kinase has been shown to bind Shc in leukemia cells (20) . Thus, one may speculate that although Shc-mediated MAP kinase activation was unchanged in vitro in the F-11 cells, a Shc-mediated change in the activation of additional downstream signaling pathways may be responsible for the increased metastatic phenotype of F-11 cells.

Metastasis of primary tumors to distant sites is a multistep process controlled by numerous growth factors. Many of these growth factors activate Shc. In the current study, we found that p66 Shc expression increased in a highly metastatic variant of the human breast cancer cell line MDA-MB-231. This xenograft observation was validated by the finding that p66 Shc increased in lymph node-positive breast tumors and that increased levels of p66 Shc correlated with an increased number of positive nodes. These data suggest that Shc may function in the metastatic pathway. Interestingly, only one of the three Shc isoforms, p66, increased in the more metastatic cell line and in the node-positive primary breast cancer specimens. Determining the upstream effectors and downstream regulators of p66 Shc function may help identify the mechanisms responsible for breast cancer metastasis. Moreover, because levels of p66 Shc found in primary breast cancer specimens correlated with lymph node involvement, measurement of p66 Shc could have prognostic implications in breast cancer.

	FOOTNOTES

 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ Supported by USPHS Grant R01CA74285 and USPHS Cancer Center Support Grant P30CA54174.

² To whom requests for reprints should be addressed. Present address: Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota Cancer Center, Box 806 Mayo, 420 Delaware Street SE, Minneapolis, MN 55455. Phone: (612) 626-8487; Fax: (612) 626-4842; E-mail: yeexx006{at}tc.umn.edu

³ The abbreviations used are: EGF, epidermal growth factor; IGF, insulin-like growth factor; SH2, src homology 2; PTB, protein tyrosine binding; SFM, serum-free medium; ER, estrogen receptor; PgR, progesterone receptor; MAP, mitogen-activated protein; TNESV, 50 mM Tris (pH 7.4), 1% NP40, 2 mM EDTA, 100 mM NaCl, 10 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride, 20 µg/ml leupeptin, and 20 µg/ml aprotinin.

⁴ T. Yoneda, P. J. Williams, T. Hiraga, M. Niewolna, and R. Nishimura. Differing properties of bone- and brain-seeking subclones of the human breast cancer cell line MDA-MB-231, submitted for publication.

Received 9/23/99; revised 11/29/99; accepted 12/15/99.

	REFERENCES

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 

1. Fidler I. J., Kumar R., Bielenberg D. R., Ellis L. M. Molecular determinants of angiogenesis in cancer metastasis. Cancer J. Sci. Am., 4: S58-S66, 1999.
2. Engebraaten O., Bjerkvig R., Pedersen P. H., Laerum O. D. Effects of EGF, bFGF, NGF, and PDGF(bb) on cell proliferative, migratory, and invasive capacities of human brain-tumour biopsies in vitro. Int. J. Cancer, 53: 209-214, 1993.[Medline]
3. Sachs M., Weidner K. M., Brinkmann V., Walther I., Obermeier A., Ullrich A., Birchmeier W. Motogenic and morphogenic activity of epithelial receptor tyrosine kinases. J. Cell Biol., 133: 1095-1107, 1996.[Abstract/Free Full Text]
4. Mignatti P., Morimoto T., Rifkin D. B. Basic fibroblast growth factor released by single, isolated cells stimulates their migration in an autocrine manner. Proc. Natl. Acad. Sci. USA, 88: 11007-11011, 1991.[Abstract/Free Full Text]
5. Taylor W. R., Greenberg A. H., Turley E. A., Wright J. A. Cell motility, invasion, and malignancy induced by overexpression of K-FGF or bFGF. Exp. Cell Res., 204: 295-301, 1993.[CrossRef][Medline]
6. Choudhury G. G., Karamitsos C., Hernandez J., Gentilini A., Bardgette J., Abboud H. E. PI-3-kinase and MAPK regulate mesangial cell proliferation and migration in response to PDGF. Am. J. Physiol., 273: F931-F938, 1997.
7. Hamada J., Nagayasu H., Takayama M., Kawano T., Hosokawa M., Takeichi N. Enhanced effect of epidermal growth factor on pulmonary metastasis and in vitro invasion of rat mammary carcinoma cells. Cancer Lett., 89: 161-167, 1995.[CrossRef][Medline]
8. Pelicci, G., Giordano, S., Zhen, Z., Salcini, A. E., Lanfrancone, L., Bardelli, A., Panayotou, G., Waterfield, M. D., Ponzetto, C., and Pelicci, P. G. The motogenic and mitogenic responses to HGF are amplified by the Shc adaptor protein. Oncogene, 10: 1631–1638, 1995.
9. Ratner S., Patrick P., Bora G. Lymphocyte development of adherence and motility in extracellular matrix during IL-2 stimulation. J. Immunol., 149: 681-688, 1992.[Abstract]
10. Stracke M. L., Engel J. D., Wilson L. W., Rechler M. M., Liotta L. A., Schiffmann E. The type I insulin-like growth factor receptor is a motility receptor in human melanoma cells. J. Biol. Chem., 264: 21544-21549, 1989.[Abstract/Free Full Text]
11. Migliaccio E., Mele S., Salcini A. E., Pelicci G., Lai K. M., Superti-Furga G., Pawson T., Di Fiore P. P., Lanfrancone L., Pelicci P. G. Opposite effects of the p52shc/p46shc and p66shc splicing isoforms on the EGF receptor-MAP kinase-fos signalling pathway. EMBO J., 16: 706-716, 1997.[CrossRef][Medline]
12. Webster M. A., Hutchinson J. N., Rauh M. J., Muthuswamy S. K., Anton M., Tortorice C. G., Cardiff R. D., Graham F. L., Hassell J. A., Muller W. J. Requirement for both Shc and phosphatidylinositol 3' kinase signaling pathways in polyomavirus middle T-mediated mammary tumorigenesis. Mol. Cell. Biol., 18: 2344-2359, 1998.[Abstract/Free Full Text]
13. Yee D., McGuire S. E., Brunner N., Kozelsky T. W., Allred D. C., Chen S. H., Woo S. L. C. Adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase in an ascites model of human breast cancer. Hum. Gene Ther., 7: 1251-1257, 1996.[Medline]
14. Lee A. V., Jackson J. G., Gooch J. G., Hilsenbeck S. G., Coronado-Heinsohn E., Osborne C. K., Yee D. Enhancement of the insulin-like growth factor pathway by estrogen in human breast cancer cells. Mol. Endocrinol., 13: 787-796, 1999.[Abstract/Free Full Text]
15. Okada S., Kao A. W., Ceresa B. P., Blaikie P., Margolis B., Pessin J. E. The 66-kDa Shc isoform is a negative regulator of the epidermal growth factor-stimulated mitogen-activated protein kinase pathway. J. Biol. Chem., 272: 28042-28049, 1997.[Abstract/Free Full Text]
16. Johnson G. L. Signal transduction abnormalities in cancer mitogen-activated protein kinase regulation is altered in breast cancer. J. Clin. Investig., 99: 1463-1464, 1997.[Medline]
17. Gotoh N., Toyoda M., Shibuya M. Tyrosine phosphorylation sites at amino acids 239 and 240 of Shc are involved in epidermal growth factor-induced mitogenic signaling that is distinct from Ras/mitogen-activated protein kinase activation. Mol. Cell. Biol., 17: 1824-1831, 1997.[Abstract]
18. Gotoh N., Tojo A., Shibuya M. A novel pathway from phosphorylation of tyrosine residues 239/240 of Shc, contributing to suppress apoptosis by IL-3. EMBO J., 15: 6197-6204, 1996.[Medline]
19. van der Geer P., Wiley S., Gish G. D., Pawson T. The Shc adaptor protein is highly phosphorylated at conserved, twin tyrosine residues (Y239/240) that mediate protein-protein interactions. Curr. Biol., 6: 1435-1444, 1996.[CrossRef][Medline]
20. Harrison-Findik D., Susa M., Varticovski L. Association of phosphatidylinositol 3-kinase with SHC in chronic myelogeneous leukemia cells. Oncogene, 10: 1385-1391, 1995.[Medline]

This article has been cited by other articles:

				G. Xi, X. Shen, and D. R. Clemmons p66shc Negatively Regulates Insulin-Like Growth Factor I Signal Transduction via Inhibition of p52shc Binding to Src Homology 2 Domain-Containing Protein Tyrosine Phosphatase Substrate-1 Leading to Impaired Growth Factor Receptor-Bound Protein-2 Membrane Recruitment Mol. Endocrinol., September 1, 2008; 22(9): 2162 - 2175. [Abstract] [Full Text] [PDF]

				A. Chahdi and A. Sorokin Endothelin-1 Couples {beta}Pix to p66Shc: Role of {beta}Pix in Cell Proliferation through FOXO3a Phosphorylation and p27kip1 Down-Regulation Independently of Akt Mol. Biol. Cell, June 1, 2008; 19(6): 2609 - 2619. [Abstract] [Full Text] [PDF]

				M. Gertz, F. Fischer, D. Wolters, and C. Steegborn Activation of the lifespan regulator p66Shc through reversible disulfide bond formation PNAS, April 15, 2008; 105(15): 5705 - 5709. [Abstract] [Full Text] [PDF]

				P. Sansone, G. Storci, C. Giovannini, S. Pandolfi, S. Pianetti, M. Taffurelli, D. Santini, C. Ceccarelli, P. Chieco, and M. Bonafe p66Shc/Notch-3 Interplay Controls Self-Renewal and Hypoxia Survival in Human Stem/Progenitor Cells of the Mammary Gland Expanded In Vitro as Mammospheres Stem Cells, March 1, 2007; 25(3): 807 - 815. [Abstract] [Full Text] [PDF]

				S. Hiscox, L Morgan, T. Green, and R. I Nicholson Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer Endocr. Relat. Cancer, December 1, 2006; 13(Supplement_1): S53 - S59. [Abstract] [Full Text] [PDF]

				S. De, O. Razorenova, N. P. McCabe, T. O'Toole, J. Qin, and T. V. Byzova VEGF-integrin interplay controls tumor growth and vascularization PNAS, May 24, 2005; 102(21): 7589 - 7594. [Abstract] [Full Text] [PDF]

				G. Loughran, N. C. Healy, P. A. Kiely, M. Huigsloot, N. L. Kedersha, and R. O'Connor Mystique Is a New Insulin-like Growth Factor-I-regulated PDZ-LIM Domain Protein That Promotes Cell Attachment and Migration and Suppresses Anchorage-independent Growth Mol. Biol. Cell, April 1, 2005; 16(4): 1811 - 1822. [Abstract] [Full Text] [PDF]

				U. Sivaprasad, J. Fleming, P. S. Verma, K. A. Hogan, G. Desury, and W. S. Cohick Stimulation of Insulin-Like Growth Factor (IGF) Binding Protein-3 Synthesis by IGF-I and Transforming Growth Factor-{alpha} Is Mediated by Both Phosphatidylinositol-3 Kinase and Mitogen-Activated Protein Kinase Pathways in Mammary Epithelial Cells Endocrinology, September 1, 2004; 145(9): 4213 - 4221. [Abstract] [Full Text] [PDF]

				A. Ventura, L. Luzi, S. Pacini, C. T. Baldari, and P. G. Pelicci The p66Shc Longevity Gene Is Silenced through Epigenetic Modifications of an Alternative Promoter J. Biol. Chem., June 14, 2002; 277(25): 22370 - 22376. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jackson, J. G. Articles by Yee, D. Search for Related Content PubMed PubMed Citation Articles by Jackson, J. G. Articles by Yee, D.